Esperion Therapeutics, Inc.
ESPRdata completeness 88%15 fiscal years on filei. The business — what you’d actually own
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $78.4M1 | $75.5M2 | $116.3M3 | $332.3M3 | $403.1M3 |
| Net income | −$269.1M4 | −$233.7M5 | −$209.2M6 | −$51.7M6 | −$22.7M6 |
| Operating cash flow | −$263.8M7 | −$174.8M8 | −$135.5M9 | −$23.7M9 | −$13.1M9 |
| Capital expenditure | $010 | $011 | $012 | $317,00012 | $012 |
| Free cash flow (derived) | −$263.8M7 | −$174.8M8 | −$135.5M9 | −$24M9 | −$13.1M9 |
| Total debt | — | — | — | — | — |
| Cash & equivalents | $208.9M13 | $124.8M14 | $82.2M15 | $144.8M16 | $167.9M16 |
| Diluted shares | 28.9M | 66.4M | 103.1M | 187.2M | 207.9M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$14.53
your share of equity
Profit it earned you last year
−$1.09
Free cash flow it threw off
−$0.63
Debt you’d be carrying
—
10 shares is a claim on −$14.53 of net worth that earned you −$1.09 and generated −$0.63 of cash last year.
iii. Is this a good business?
Moat signal · return on equity
— avg · 5y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
+619% shares · 5y
Share count is up 619% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 10-K · period ending 2021-12-31 · accession 0001628280-23-004167 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0001628280-25-011154 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001628280-26-016522 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001628280-23-004167 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001628280-25-011154 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001628280-26-016522 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001628280-23-004167 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001628280-25-011154 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001628280-26-016522 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001628280-22-003263 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001628280-25-011154 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001628280-26-016522 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001628280-23-004167 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001628280-24-007066 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001628280-25-011154 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001628280-26-016522 (CashAndCashEquivalentsAtCarryingValue)